Lantus

Lantus is a brand name for insulin glargine, a long-acting insulin analog used to improve glycemic control in adults and children with type 1 diabetes or type 2 diabetes. It provides a steady basal level of insulin to help manage blood glucose between meals and overnight.

Pharmacology and use: Insulin glargine is produced by recombinant DNA technology and is administered by subcutaneous injection. At physiological pH it forms micro-precipitates that release insulin slowly, producing a relatively flat time‑action profile with no pronounced peak. The onset of action is about 1 to 2 hours, and the duration is roughly 24 hours, though individual response can vary. Lantus is not approved for intravenous use.

Dosing and administration: Lantus is typically given once daily at the same time each day, with adjustments made to achieve fasting glucose targets. Some patients may require dosing every 12 hours. It is commonly used as the basal component in a broader insulin regimen, often in combination with rapid-acting insulin for mealtime coverage. Do not mix Lantus in the same syringe with other insulins. Inject subcutaneously in areas such as the abdomen, thigh, or upper arm, and rotate injection sites to reduce tissue damage.

Formulations and availability: Lantus is supplied as U-100 insulin glargine in vials and prefilled SoloStar pens. A higher-concentration U-300 formulation (Toujeo) is a separate product. Biosimilar insulin glargine products, such as Basaglar, are available in various markets.

Safety and storage: Common adverse effects include hypoglycemia, weight gain, edema, and injection site reactions; lipodystrophy at injection sites may occur with repeated use. Unopened vials or pens should be refrigerated; after first use, Lantus products may be stored at room temperature and used for a limited period (per label directions). Users should monitor for signs of hypoglycemia and adjust dosing with medical guidance.